Kymera Therapeutics (KYMR) Expected to Post Quarterly Earnings on Thursday

Key Points

• Kymera Therapeutics is expected to report Q3 2026 results before market open on October 29. Analysts forecast a loss of $1.27 per share and revenue of $3.10 million; the earnings call is scheduled for October 28 at 8:30 a.m. ET.
• The company’s previous quarter exceeded expectations, with a loss of $0.62 per share versus the $0.71 consensus estimate and revenue of $65 million, up 465.2% year over year.
• Wall Street maintains a generally positive view, with a “Moderate Buy” consensus rating and an average price target of $134.68, compared with a recent share price of $110.76.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Kymera Therapeutics to post earnings of ($1.27) per share and revenue of $3.10 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:30 AM ET.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. The company had revenue of $65.00 million during the quarter, compared to analysts' expectations of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm's revenue for the quarter was up 465.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) EPS. On average, analysts expect Kymera Therapeutics to post ($3.85) EPS for the current fiscal year and ($5.09) EPS for the next fiscal year.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $110.76 on Friday. The company has a market capitalization of $9.21 billion, a P/E ratio of -34.19 and a beta of 1.98. The stock has a 50-day moving average price of $115.03 and a 200 day moving average price of $101.98. Kymera Therapeutics has a one year low of $55.66 and a one year high of $130.05.

Wall Street Analyst Weigh In

A number of research firms have commented on KYMR. Citigroup increased their price objective on shares of Kymera Therapeutics from $135.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, October 5th. Royal Bank Of Canada lowered Kymera Therapeutics from an "outperform" rating to a "sector perform" rating and upped their price target for the company from $106.00 to $115.00 in a research report on Monday, July 13th. Bank of America raised their price objective on Kymera Therapeutics from $123.00 to $144.00 and gave the stock a "buy" rating in a research note on Monday, September 14th. Morgan Stanley reaffirmed an "overweight" rating and issued a $135.00 price objective on shares of Kymera Therapeutics in a report on Thursday, August 6th. Finally, Stifel Nicolaus boosted their target price on shares of Kymera Therapeutics from $132.00 to $152.00 and gave the company a "buy" rating in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Kymera Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $134.68.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Brian Adams sold 6,371 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the completion of the transaction, the insider owned 50,254 shares in the company, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company's stock, valued at $75,855,438.40. This represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. 15.98% of the stock is owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell's natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company's research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.